NCT02444819

Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy

A Multicenter, Single-arm, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line Anticancer Agent in NSCLC Patients With EGFR Mutation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A multi-center, single-arm. Phase 2 exploratory trial to evaluate the efficacy and safety of HM61713 as the 1st-line anticancer agent in none-small cell lung cancer patients with EGFR mutation

Detailed description

HM-EMSI-201 study targets NSCLC patients with EGFR mutations by HM61713 anticancer drug as the first-line therapy.

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	HM61713	HM61713 will be administered to evaluate efficacy and safety of subjects.

Timeline

• Start date: 2015-03-01
• Primary completion: 2017-08-01
• Completion: 2017-08-01
• First posted: 2015-05-15
• Last updated: 2018-04-24

Locations

1 site across 1 country: South Korea